Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies
The DOI matches its Crossref record; 83 of the 84 references it cites were found in a registry or an index.
Abstract
The long serum t1/2 of IgGs is ensured by their interaction with the neonatal Fc receptor (FcRn), which salvages IgG from intracellular degradation. Fc glycosylation is thought not to influence FcRn binding and IgG longevity in vivo. In this article, we demonstrate that hypersialylation of asparagine 297 (N297) enhances IgG serum persistence. This polarized glycosylation is achieved using a novel Fc mutation, a glutamate residue deletion at position 294 (Del) that endows IgGs with an up to 9-fold increase in serum lifespan. The strongest impact was observed when the Del was combined with Fc mutations improving FcRn binding (Del-FcRn+). Enzymatic desialylation of a Del-FcRn+ mutant or its production in a cell line unable to hypersialylate reduced the in vivo serum t1/2 of the desialylated mutants to that of native FcRn+ mutants. Consequently, our study proves that sialylation of the N297 sugar moiety has a direct impact on human IgG serum persistence.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is beneficial as more sialylated glycoforms have been shown to have a longer in vivo half‐life. 38 , 39”
From Dynamic pH profiles drive higher cell‐specific and volumetric productivity (2026) · cites this paper as [39]
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229 · cited 4×
“This medicinal prospect became reality with the advent of immortalization of Ab-producing clonal B cells following their somatic cell fusion with myeloma cells (2).”
BackgroundMethodInfluentialFcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Carbohydrate-Specific Receptors of the Liver
Ashwell, G., & Harford, J. (1982) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.51.070182.002531 · Cited by 1,914 · cited 2×
“acid on galactose residues masks the epitope, thereby inhibiting their removal from circulation (62).”
BackgroundCartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835 · cited 1×
“ably because the IgG low-fucose content already resulted in high binding to this receptor, reducing the additional impact of the mutations (15).”
BackgroundAnti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation
Kaneko, Y., Nimmerjahn, F., & Ravetch, J. V. (2006) · Science · doi:10.1126/science.1129594 · Cited by 1,754
Bruhns, P., Iannascoli, B., England, P., Mancardi, D. A., Fernandez, N., Jorieux, S., & Daëron, M. (2009) · Blood · doi:10.1182/blood-2008-09-179754 · Cited by 1,479
Self-citationPaul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457 · cited 1×
“Two assays were set up to characterize the interaction of the IgG variants with hFcRn: 1) biolayer interferometry (BLI) and 2) competitive binding assay on FcRn-expressing Jurkat cells (1).”
MethodThe Impact of Glycosylation on the Biological Function and Structure of Human Immunoglobulins
Arnold, J. N., Wormald, M. R., Sim, R. B., Rudd, P. M., & Dwek, R. A. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141702 · Cited by 1,307
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300 · cited 1×
“To eliminate sialylated residues from glycans, the IgG variant T5A-74Del was treated with sialidase A (GK80040; Prozyme) to release a(2,3)-, a(2,6)-, a(2,8)-, and a(2,9)-linked N-acetylneuraminic acid.”
Method
Cited by
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 316
“The collection of mutations were studied as individual mutations to elucidate the function of the deletion of Glu294 (115).”
BackgroundInfluentialConsiderations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 302
The history of IgG glycosylation and where we are now
Cobb, B. A. (2020) · Glycobiology · doi:10.1093/glycob/cwz065 · Cited by 193
“Indeed, Fc sialylation increases circulatory half-life of antibodies (Bas et al. 2019), likely by avoiding ligation by both the asialoglycoprotein receptor (ASGPR) in the liver and the neonatal Fc receptor FcRn.”
BackgroundThe Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
Gogesch, P., Dudek, S., van Zandbergen, G., Waibler, Z., & Anzaghe, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168947 · Cited by 172
“that hypersialylation of N297 is able to extend the half-life of IgG [170].”
BackgroundImpact of structural modifications of IgG antibodies on effector functions
Damelang, T., Brinkhaus, M., van Osch, T. L. J., Schuurman, J., Labrijn, A. F., Rispens, T., & Vidarsson, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1304365 · Cited by 123
Genetic glycoengineering in mammalian cells
Narimatsu, Y., Büll, C., Chen, Y., Wandall, H. H., Yang, Z., & Clausen, H. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100448 · Cited by 107
“This may mediate anti-inflammatory effects (285) and improve serum half-life (252), although contradicting studies report no effects of sialic acid on Fc conformation and recognition (286, 287).”
BackgroundIgG Charge: Practical and Biological Implications
Yang, D., Kroe‐Barrett, R., Singh, S., & Laue, T. M. (2019) · Antibodies · doi:10.3390/antib8010024 · Cited by 102
Antibody glycosylation in autoimmune diseases
Zhou, X., Motta, F., Selmi, C. F., Ridgway, W. M., Gershwin, M. E., & Zhang, W. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102804 · Cited by 100
Wu, R., Lao, X., Chen, D., Qin, H., Mu, M., Cao, W.-J., Deng, J., Wan, C.-C., Zhan, W.-Y., Wang, J., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.11.014 · Cited by 80
Edwards, E., Livanos, M., Krueger, A., Dell, A., Haslam, S. M., Smales, C. M., & Bracewell, D. G. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28066 · Cited by 80
“Glycosylation is known to have effects on the biological activity, solubility, serum half‐life, and safety of therapeutic antibodies (Bas et al., 2019; Narhi et al., 1991; Varki, 1993).”
BackgroundAntibody glycosylation: impact on antibody drug characteristics and quality control
Wang, Z., Zhu, J., & Lu, H. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10368-7 · Cited by 67
Therapeutic antibody glycosylation impacts antigen recognition and immunogenicity
Wolf, B., Piksa, M., Beley, I., Patoux, A., Besson, T., Cordier, V., Voedisch, B., Schindler, P. A., Stöllner, D., Perrot, L., et al. (2022) · Immunology · doi:10.1111/imm.13481 · Cited by 48
“[85] ascribe the observed increased half-life of antibodies, mutated in the Fc to increase FcRn ligation, to sialic acids independent of FcRn, FcγRIIs and structural effects.”
BackgroundAdvancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic
Spencer, D. A., Shapiro, M. B., Haigwood, N. L., & Hessell, A. J. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.690017 · Cited by 56
“While extending halflife, the E294 deletion concurrently reduced binding to FcγRIII and complement dependent lysis of infected Raji cells (105), thus its clinical advancement may be limited to contexts where eliminating these effector functions is deemed less important than maximizing half-life.”
BackgroundCao, Y., Song, Z., Guo, Z., Zhao, X., Gong, Y. Q., Zhao, K., Qu, C., Huang, Y., Li, Y., Gao, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.724379 · Cited by 53
“Sialylation of IgG has been reported to decrease its affinity to FcgRIIIa to reduce ADCC activity but enhance ADCP activity (15) and prolong the half-life of IgG in serum (51).”
BackgroundCoronaviruses: Is Sialic Acid a Gate to the Eye of Cytokine Storm? From the Entry to the Effects
Wielgat, P., Rogowski, K., Godlewska, K., & Car, H. (2020) · Cells · doi:10.3390/cells9091963 · Cited by 47
On the Use of Surface Plasmon Resonance Biosensing to Understand IgG-FcγR Interactions
Forest‐Nault, C., Gaudreault, J., Henry, O., Durocher, Y., & Crescenzo, G. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126616 · Cited by 47
Conner, K. P., Devanaboyina, S. C., Thomas, V. A., & Rock, D. A. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107574 · Cited by 41
Therapeutic antibodies for the prevention and treatment of cancer
Kumar, M., Jalota, A., Sahu, S. K., & Haque, S. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-00996-w · Cited by 39
“Fc sialylation has also been shown to increase serum half-life of therapeutic antibodies [4].”
BackgroundNguyen, N., Lin, J., Tay, S. J., Mariati, Yeo, J. H. M., Nguyen‐Khuong, T., & Yang, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-92320-x · Cited by 43
Tashima, T. (2022) · Antibodies · doi:10.3390/antib11040078 · Cited by 41
Cell factory engineering: Challenges and opportunities for synthetic biology applications
Bachhav, B., de Rossi, J., Llanos, C. P., & Segatori, L. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28365 · Cited by 36
“Similarly, the antibody's sialylation profile affects its half‐life in circulation (Bas et al., 2019), the mannosylation patterns influence its pharmacokinetics (L.”
BackgroundSchaffert, A., Hanić, M., Novokmet, M., Zaytseva, O. O., Krištić, J., Lux, A., Nitschke, L., Peipp, M., Pezer, M., Hennig, R., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03024 · Cited by 28
“For example, a more rapid clearance of select IgG isotypes or glycoforms may lead to an increase in other IgG glycoforms with a longer IgG half-life (41, 48).”
BackgroundBulk IgG Glycosylation Predicts COVID-19 Severity and Vaccine Antibody Response
Ash, M. K., Bhimalli, P. P., Cho, B.-K., Mattamana, B. B., Gambut, S., Tarhoni, I., Fhied, C. L., Reyes, A. F., Welninski, S. J., Arivalagan, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111799 · Cited by 38
IgG Glycosylation: Biomarker, Functional Modulator, and Structural Component
Radovani, B., & Nimmerjahn, F. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2400447 · Cited by 28
Online control of cell culture redox potential prevents antibody interchain disulfide bond reduction
Handlogten, M. W., Wang, J., & Ahuja, S. (2020) · Biotechnology and Bioengineering · doi:10.1002/bit.27281 · Cited by 26
Iyengar, A. R. S., Gupta, S., Jawalekar, S. S., & Pande, A. H. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.257063 · Cited by 25
“Moreover, it has been reported that hypersialylation of aspargine residue at 297 position, achieved through deletion of glutamate residue at 294, could prolong the residence of Fc in the serum (Bas et al., 2019).”
BackgroundIgG Fab Glycans Hinder FcRn-Mediated Placental Transport
Volkov, M., Brinkhaus, M., van Schie, K. A., Bondt, A., Kissel, T., van der Kooi, E. J., Bentlage, A. E. H., Koeleman, C. A. M., de Taeye, S. W., Derksen, N. I. L., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200438 · Cited by 25
Glycan-specific antibodies as potential cancer biomarkers: a focus on microarray applications
Tikhonov, A. A., Smoldovskaya, O., Feyzkhanova, G., Кушлинский, Н. Е., & Rubina, A. Y. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-1161 · Cited by 23
“Besides, it was shown that Fc hypersialylation of therapeutic antibodies might influence the IgG interaction with the neonatal Fc receptor extending the half-life of IgG by reducing their intracellular degradation [52].”
Backgroundα2,6-Sialylation Is Upregulated in Severe COVID-19, Implicating the Complement Cascade
Qin, R., Kurz, E., Chen, S., Zeck, B., Chiribogas, L., Jackson, D., Herchen, A., Attia, T., Carlock, M. A., Rapkiewicz, A., et al. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.2c00421 · Cited by 22
Hsu, Y., Nourzaie, O., Tocher, A. E., Nerella, K., Ermakov, G., Jung, J., Fowler, A., Wu, P., Ayesa, U., Willingham, A. T., et al. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00302 · Cited by 23
Sarafanov, A. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108584 · Cited by 23
“In any case, it is still interesting to investigate, in particular, if a hyper sialylation of FVIII prolongs its aging time, thus postponing its interactions with ASGPR and MGL, and extending the plasma half-life similarly to that shown for other proteins [126].”
BackgroundMao, C., Li, J., Feng, L., & Gao, W. (2023) · Antibody Therapeutics · doi:10.1093/abt/tbad004 · Cited by 29
“On the contrary, hypersialylation of IgG can significantly increase serum half-life by up to 9-fold [9].”
Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review
Regazzi, M. B., Golay, J., & Molinaro, M. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000681 · Cited by 23
Monnet, C., Jacque, É., de Romeuf, C., Fontayne, A., Abache, T., Fournier, N., Dupont, G., Derache, D., Engrand, A., Bauduin, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.728322 · Cited by 17
“An alternative anti-inflammatory mechanism was described using sialylated antibodies (29, 42, 43).”
BackgroundMethodSelf-citationKrishna, S., Jung, S. T., & Lee, E. Y. (2024) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2024.2342969 · Cited by 14
“The capping of glycan termini contributes to an increased IgG half-life in circulation [68].”
Prabhu, A., Shanmugam, D., & Gadgil, M. (2022) · Metabolic Engineering · doi:10.1016/j.ymben.2022.09.003 · Cited by 16
IgG N-glycosylation from Patients with Pemphigus Treated with Rituximab
Font, G., Walet-Balieu, M.-L., Petit, M. A., Burel, C., Maho‐Vaillant, M., Hébert, V., Chan, P., Fréret, M., Boyer, O., Joly, P., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10081774 · Cited by 14
“Moreover, recent studies showed that sialylation could prolong the serum half-life of therapeutic monoclonal antibodies [8,19].”
BackgroundEngineered Fc-glycosylation switch to eliminate antibody effector function
Zhou, Q., Jaworski, J. A., Zhou, Y., Valente, D., Cotton, J., Honey, D. M., Boudanova, E., Beninga, J., Rao, E., Wei, R. R., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1814583 · Cited by 14
“reported that Fc-sialylation also displays synergistically prolonged PK profile of antibody when it was combined with mutation for enhanced FcRn binding.(38) Therefore, our NNAS Fc could be a very useful fusion partner for half-life extension of wild-type antibodies and other Fc mutants, especially if combined with su…”
BackgroundStructural and Functional Roles of the N-Glycans in Therapeutic Antibodies
Yagi, H., Yanaka, S., & Kato, K. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819475-1.00044-4 · Cited by 13
Sweet Rules: Linking Glycosylation to Antibody Function
Nimmerjahn, F., & Werner, A. (2021) · Experientia supplementum · doi:10.1007/978-3-030-76912-3_12 · Cited by 14
Modified Therapeutic Antibodies: Improving Efficacy
Dai, J., Zhang, X., Dai, J., Yang, X.-M., & Chen, Z. (2021) · Engineering · doi:10.1016/j.eng.2020.06.030 · Cited by 14
Perdomo‐Abúndez, F. C., Vallejo‐Castillo, L., Vázquez‐Leyva, S., López‐Morales, C. A., Velasco-Velázquez, M. A., Pavón, L., Pérez‐Tapia, S. M., & Medina‐Rivero, E. (2019) · Journal of Chromatography B · doi:10.1016/j.jchromb.2019.121885 · Cited by 10
Infection and the Glycome─New Insights into Host Response
Mohideen, F. I., & Mahal, L. K. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00315 · Cited by 12
Mahant, A. M., Trejo, F. A. E., Aguilan, J. T., Sidoli, S., Permar, S. R., & Herold, B. C. (2023) · iScience · doi:10.1016/j.isci.2023.107648 · Cited by 10
“To assess this, we quantified the apparent affinity for the FcRn.”
BackgroundGyorgypal, A., Fratz‐Berilla, E. J., Kohnhorst, C. L., Powers, D. N., & Chundawat, S. P. S. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.28999 · Cited by 17
“Terminal sialic acids have been demonstrated to increase serum persistence and modulate anti ‐ inflammatory activity (Bas et al. 2019; Böhm et al. 2012).”
Blaschke, C. R. K., Hill, E. G., Mehta, A. S., Angel, P. M., Laronga, C., & Drake, R. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-25401-0 · Cited by 10
Orr, A. A., Tao, A., Guvench, O., & MacKerell, A. D. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00064 · Cited by 8
Enhanced transglycosylation activity of an Endo-F3 mutant by ligand-directed localization
Zou, X., Liu, Z., Liu, L., Shi, W., Li, W., Guo, Z., Tang, F., & Huang, W. (2022) · Organic & Biomolecular Chemistry · doi:10.1039/d2ob00030j · Cited by 8
Need for a risk-based control strategy for managing glycosylation profile for biosimilar products
Rathore, A. S., & Malani, H. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1973425 · Cited by 8
“tions of mAb (~9x more than asialo counterpart) by shielding it from ASGPR and also affects bioactivity [35].”
BackgroundAt-line quantitative profiling of monoclonal antibody products during bioprocessing using HPLC-MS
Böttinger, K., Esser‐Skala, W., Segl, M., Herwig, C., & Huber, C. G. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2022.339813 · Cited by 10
Immunoglobulin G Subclass-Specific Glycosylation Changes in Rheumatoid Arthritis
Szabo, D. A., Gyebrovszki, B., Szarka, E., Auer, F., Rojkovich, B., Nagy, G., Telekes, A., Vékey, K., Drahos, L., Ács, A., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199626 · Cited by 8
“Increased sialylation has been found to extend the serum half-life of monoclonal antibodies [28].”
Chakrabarti, A., Kervinen, J., Müller, E., Tanaka, T., & Muranaka, K. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95356 · Cited by 6
IgG sialylation occurs via the FcRn-mediated recycling pathway in endothelial cellsPreprint
Glendenning, L. M., Reynero, K. M., Kukan, E. N., Long, M. D., & Cobb, B. A. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.30.547255 · Cited by 6
“As IgG half-life also correlates with IgG sialylation ( 30 ), we hypothesized that IgG isolated from the plasma of FcRnKO animals would also be deficient in IgG sialylation.”
BackgroundMihaila, R., Ruhela, D., Xu, L., Joussef, S., Geng, X., Shi, J., Kim, A. S., Yares, W., Furstoss, K., & Iverson, K. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2143260 · Cited by 5
“Sialylation is an important characteristic of glycoproteins that can affect their potency, half-life, and immunogenicity by salvaging glycoproteins from degradation [26].”
BackgroundPeters, B., Bautista, J., Slaney, T. R., Guo, H., Huang, R. Y. ‐., Krause, M. E., Zeng, M., Cheng, J. W.-C., & Chen, Z. (2022) · Electrophoresis · doi:10.1002/elps.202100259 · Cited by 5
Yin, P., Lin, H., Zhou, Q., Tong, J., & Guo, M. (2025) · Cytotechnology · doi:10.1007/s10616-025-00816-5 · Cited by 6
“…tissue retention and whole body clearance (Boswell et al. 2010; Schoch et al. 2015; Yadav et al. 2015); N-glycosylation of mAbs has been reported to have influence on stability, effector functions and immunogenicity and pharmacokinetics (Ivarsson et al. 2014; Bas et al. 2019; Boune et al. 2020).”
Sperinde, G. V., Liu, L., Xu, K., Bentley, T., Sukumaran, S., Lutman, J., Huang, C., Williams, K., Hokom, M. M., & Fischer, S. K. (2021) · Bioanalysis · doi:10.4155/bio-2021-0186 · Cited by 4
Endothelial cells sialylate IgG within the FcRn-mediated recycling pathway
Glendenning, L. M., Long, M. D., Carlson, G. C., Silva, A. D., Wang, S., Reynero, K. M., Kukan, E. N., Bellis, S. L., Goodman, W. A., & Cobb, B. A. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2511216122 · Cited by 8
“As IgG half - life is increased with IgG sialylation (40, 41), we hypothesized that IgG isolated from the plasma of FcRnKO animals would also be deficient in sialylation.”
Yan, R., Wang, C., Zhao, X., Wang, Y., Liu, M., Shí, X., Chen, H., & Li, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1758338 · Cited by 4
Chen, Y., Li, X., Lu, R., Lv, Y., Ye, J., Huang, Q., Meng, W., Long, F., Burman, J., Mo, X., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1326370 · Cited by 3
Alkanaimsh, S., AlSalal, A. M., & El-Touney, H. (2024) · Processes · doi:10.3390/pr12050979 · Cited by 3
Chen, Z., Xu, X., Song, M., & Lin, L. (2024) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2024.0176 · Cited by 4
“In addition, decreased terminal mannose and increased G or S enhance the binding af fi nity of IgG to the neonatal Fc receptor, which extends its half-life, as shown in Figure 1 (Bas et al., 2019; Goetze et al., 2011; Wang et al., 2020).”
Gyorgypal, A., Fratz‐Berilla, E. J., Kohnhorst, C. L., Powers, D. N., & Chundawat, S. P. S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.15.535602 · Cited by 3
Shull, T. L., Bhimalli, P. P., Welninski, S. J., Cho, B.-K., Mattamana, B. B., Arivalagan, J., Tarhoni, I., Goo, Y. A., Schneider, J. A., Agrawal, S., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.03.031 · Cited by 2
Kim, K. H., Ji, E. S., Lee, J. Y., Song, J. H., & Ahn, Y. H. (2024) · Molecules · doi:10.3390/molecules29225393 · Cited by 2
Pranomphon, R., Tejwani, V., Dahodwala, H., Yamabhai, M., & Sharfstein, S. T. (2024) · Springer eBooks · doi:10.1007/978-3-031-62007-2_6 · Cited by 3
Yates, J. L., Palat, D. S., Subik, M. K., Lee, W. T., McDonough, K. A., & Conuel, E. J. (2022) · Clinical Immunology Communications · doi:10.1016/j.clicom.2022.03.001 · Cited by 2
Sialylated autoantibodies involved in disease activity of rheumatoid arthritis
Lee, F., Lee, W.-L., & Wang, P. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000480 · Cited by 2
Dynamic pH profiles drive higher cell‐specific and volumetric productivity
Klaubert, S. R., Chitwood, D. G., Peng, D., Redman, E., Anderson, J. Y. L., Sandoval, N. R., & Harcum, S. W. (2026) · Biotechnology Progress · doi:10.1002/btpr.70080 · Cited by 3
“38,39 There is no statistical difference in fucosylation when implementing the dynamic pH profile.”
AANL6 is a new efficient tool to probe non-reducing N-acetylglucosamine of N-linked glycans
Su, Y., Li, Y., Meng, T., Xu, B., Zhu, H., Zhang, L., Wang, X., Liu, X., & Sun, H. Z. (2023) · Carbohydrate Research · doi:10.1016/j.carres.2023.108858 · Cited by 2
Pharmacokinetic considerations and strategies for antibody-based therapeutics
Zhang, J., Chang, R., Zhao, A., Li, X., Sun, Y., Zhang, J., Wang, R., & Jin, T. (2025) · Drug Metabolism Reviews · doi:10.1080/03602532.2025.2595941 · Cited by 4
“…the hypercatalytic methylation of asparagine 297 enhances the persistence of igG serum. this polarization glycosylation can be achieved through Fc mutation, which results in the loss of glutamate residue at position 294, ultimately increasing the serum lifespan of igG by 9-fold (Bas et al. 2019).”
Gstöttner, C., Kaur, H., & Wuhrer, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822318-5.00002-8 · Cited by 1
Tao, X., Sukumaran, S., Sperinde, G. V., Liu, C., Beardsley, M. I., Day, P., Kalo, M. S., Ayewoh, E. N., Cai, H., Wang, Y., et al. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.03.016 · Cited by 3
Xu, Z. (2020) · ScholarlyCommons (University of Pennsylvania)
Generalov, R., Fiorito, E., Foss, S., Pascal, V., Heyerdahl, H., Repetto‐Llamazares, A. H. V., Andersen, J. T., Tjønnfjord, G. E., Skånland, S. S., & Dahle, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.12.548667
Lee, S. Y., Kim, H. S., Kim, Y. G., Shin, S., Kweon, S., Lee, G. M., & Lee, G. M. (2025) · Metabolic Engineering · doi:10.1016/j.ymben.2025.10.008
Pishgahzadeh, E., Bozorgchami, N., Talebi, M., Masoudifar, R., Ahmadi, M., & Ghorbani-Bidkorpeh, F. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126319 · Cited by 1
Antibody glycosylation in neuroimmune diseases
Li, K., Luo, M., Xu, L., Ouyang, Y., Zhou, Q., Xiang, W., Ren, Y., Wen, Z., Shi, G., Luo, Z., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07611-y · Cited by 2
“Moreover, adjusting the antibody glycosylation pattern allows antibodies to better bind to the FcRn receptor in the body, prolonging the half-life of antibody drugs in the blood circulation, reducing the frequency of administration, and improving patient compliance [128, 129].”
Ercan, A. (2025) · Erciyes Üniversitesi Fen Bilimleri Enstitüsü Fen Bilimleri Dergisi · doi:10.65520/erciyesfen.1789878
Impact of monoclonal antibody diversity on in vitro diagnostics
Kozuka, N., Yoshikawa, K., & Sato, J. (2026) · SEIBUTSU BUTSURI KAGAKU · doi:10.2198/electroph.70.21
Influence des anticorps anti-Neu5Gc et anti-alpha-1-3-Galactose dans la réponse immunitaire
Rousse, J. (2019) · theses.fr (ABES) · doi:10.70675/4b032d03z011bz4593zba51zf37eb1e47a25
Tolksdorf, F., Nelke, J., Johannson, R., Caesar, J., Chaturvedi, A., Kopp, A., Fischer, L., Malz, A., Kratochvil, S., Gerhard, I., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103102 · Cited by 1
“23,24 With the exception of the Fc mutations described below, the PGT121 RibobNAb variants are identical to the PGT121 reference protein in amino acid sequence.”
Metadata
- Authors
- Bas, M., Terrier, A., Jacque, E., Dehenne, A., Pochet-Béghin, V., Beghin, C., Dezetter, A.-S., Dupont, G., Engrand, A., Beaufils, B., Mondon, P., Fournier, N., de Romeuf, C., Jorieux, S., Fontayne, A., Mars, L. T., & Monnet, C.
- Affiliations
- Inserm (FR)
- LFB (France) (FR)
- LFB Biotechnologies , 91958 Courtaboeuf Cedex ,
- LFB Biotechnologies , 59011 Lille Cedex ,
- Corresponding author
- Bas, Mathilde
- Dupont, Gilles
- Mondon, Philippe
- Fournier, Nathalie
- Jorieux, Sylvie
- Fontayne, Alexandre
- ORCID
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-03-01
- Volume
- 202
- Issue
- 5
- Pages
- 1582-1594
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2912324466
- Cited by
- 82
- References
- 84
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 11 · 2023: 11 · 2022: 15 · 2021: 13 · 2020: 10 · 2019: 8
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-17-CE15-0028)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Keywords
- neonatal Fc receptor, Fc glycosylation, FcRn binding, therapeutic antibodies, desialylation, antibody persistence
- MeSH terms
- Animals, Antibodies, Half-Life, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Mice, Knockout, Mice, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.